What Is The Current and Historic Market Size Analysis Of The Pneumonia Therapeutics Market?
The pneumonia therapeutics market has seen considerable growth due to a variety of factors.
• In the past few years, the size of the pneumonia therapeutics market has experienced a rapid expansion. The market is set to grow from $10.35 billion in 2024 to $11.49 billion in 2025, showcasing a compound annual growth rate (CAGR) of 11.0%.
The expansion during the past period can be associated with the surge in drug-resistant strains, increased consciousness about pneumonia prevention, a rise in the elderly and immunocompromised populations, the broadening of vaccination campaigns, and the enhancement of healthcare infrastructure.
What are the Market Size and Expected Growth Rates for the Pneumonia Therapeutics Market?
The pneumonia therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• Rapid expansion is expected in the pneumonia therapeutics market within the upcoming years, predicted to reach $17.26 billion in 2029, boasting a compound annual growth rate (CAGR) of 10.7%.
This surge in the forecast period can be linked to variables such as the rise of antibiotic-resistant strains, increasing pneumonia prevalence among aging populations, expanded use of telemedicine for early detection, growth in health care spending in emerging economies, escalated funding for research on infectious diseases, and more public awareness initiatives. Significant trends projected within the forecast period involve the creation of monoclonal antibodies, use of inhalable antibiotics, advancements in mRNA-based vaccines, AI-powered diagnostic devices, embracement of host-targeted therapies, development of new immunomodulators, and the progress in swift point-of-care diagnostic podiums.
Which Key Drivers Are Propelling The Pneumonia Therapeutics Market's Growth?
The expected escalation of pneumonia occurrences is predicted to propel the expansion of the pneumonia therapeutics market in the near future. Pneumonia is described as an infection in the lungs which inflames the air sacs, often leading to symptoms such as fever, cough, and respiratory difficulties. A rise in pneumonia cases can be linked to various factors including aging populations, smoking, air pollution, weakened immune systems, antimicrobial resistance, and the transmission of respiratory infections like COVID-19 or influenza. Pneumonia therapeutics work to fight the infection's source, be it bacteria, viruses, or fungi, with specific medications while facilitating recovery through oxygen therapy, anti-inflammatory drugs, and symptom control. To illustrate, the National Center for Biotechnology Information, a US government agency, reported in January 2023 that an estimated 120 million people worldwide are afflicted by pneumonia each year, resulting in around 1.3 million mortalities. Almost 80% of pneumonia fatalities in children happen in those below 2 years in developing nations. Hence, the escalating prevalence of pneumonia is accelerating the growth of the pneumonia therapeutics market.
What Are The Key Segments Within The Global Pneumonia Therapeutics Market?
The pneumonia therapeutics market covered in this report is segmented –
1) By Product: Drugs, Vaccine, Oxygen Therapy
2) By Infection: Hospital-Acquired Pneumonia (HAP), Community-Acquired Pneumonia (CAP), Ventilator-Associated Pneumonia (VAP)
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End Use: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Drugs: Antibiotics, Antiviral Drugs, Antifungal Drugs, Corticosteroids, Other Drugs
2) By Vaccine: Pneumococcal Vaccines, Haemophilus Influenzae Type B (Hib) Vaccines, Influenza Vaccines, Other Vaccines
3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC), Non-Invasive Ventilation (NIV), Mechanical Ventilation, Other Oxygen Therapies
Pre-Book The Pneumonia Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Pneumonia Therapeutics Market?
Key players in the pneumonia therapeutics market are honing their efforts on the creation of innovative drug formulations and treatment methods such as antibiotic drugs, aiming to combat antibiotic resistance and enhance patient outcomes. Antibiotic drugs are medications explicitly tailored to treat bacterial infections. To illustrate this, Orchid Pharma Limited, a pharmaceutical firm based in India, joined forces with Cipla Limited, another Indian pharmaceutical enterprise, in June 2024. The result of this collaboration was the introduction of cefepime-enmetazobactam, an antibiotic mix utilized in the treatment of multifaceted infections, including UTIs and pneumonia, especially if they proved resistant to other available drugs. This combination plays a crucial role in fighting bacterial resistance and maximizes effective treatment, lowering the necessity for more potent antibiotics.
Who Are the Key Players In The Pneumonia Therapeutics Market?
Major companies operating in the pneumonia therapeutics market are:
• Pfizer Inc.
• Roche AG
• Merck & Co. Inc.
• AbbVie Inc
• Bayer AG
• Sanofi S.A.
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• GSK plc
• Eli Lilly and Company
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Cipla Inc.
• Hikma Pharmaceuticals PLC
• Shionogi & Co. Ltd
• Lupin Limited
• Swedish Orphan Biovitrum AB
• Nabriva Therapeutics plc
• TaiGen Biotechnology Co. Ltd
• Aridis Pharmaceuticals Inc.
• Tergene Biotech Limited.
What Are The Regional Insights Into The Pneumonia Therapeutics Market?
North America was the largest region in the pneumonia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumonia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
